Clinical Trial

Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 18, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Colistin can be used to treat the infection caused by carbapenem-resistant enterobacteriaceae(CRE). In China, patients diagnosed with Hospital-acquired-pneumonia (HAP)or bloodstream infection caused by CRE are recruited, and randomly assigned to two groups, and in one group the patients accept treatment with colistin, however in another group, the patients accept treatment without colistin. The efficacy and safety of the treatment between the two groups are compared.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-09-20; most recent amendment 2025-05-14.
Status change: Not Yet Recruiting → Recruiting 2024-03-10
Trial Details
NCT Number NCT06051513
Lead Sponsor Southeast University, China
Conditions Carbapenem-Resistant Enterobacteriaceae Infection
Enrollment 404 participants
Start Date 2023-11-27
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-18